RxDoctor Payments Data

Prodyot Ghosh, MD

Gastroenterology · Bloomington, INNPI 1780689257

Payments from drug & device makers

$1,897in general payments, 2019–2025

Across 39 payments — averaging $48.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$386
  • Johnson & Johnson$332
  • Boston Scientific$309
  • E.r. Squibb & Sons, L.L.C.$190
  • Perspectum Diagnostics Ltd$174
  • Medtronic$139
  • plus $368 from 8 others

What the payments were for

  • Food & beverage$1,88399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,897 in reported general payments places this provider in the 45th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana

Medicare billing

Part B allowed, 2024
$140,878
Medicare patients
707
Services billed
1,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab25$169,926
XifaxanRifaximin13$39,497
LinzessLinaclotide42$22,544
CreonLipase/Protease/Amylase18$19,933
Budesonide EcBudesonide27$12,555
Colesevelam Hcl17$3,961
SutabSod Sulf/Pot Chloride/Mag Sulf14$2,341
Omeprazole170$2,079
Azathioprine25$1,664
Colestipol Hcl21$1,158
Dicyclomine Hcl28$1,043
Pantoprazole Sodium82$970
Famotidine62$933
Ondansetron OdtOndansetron37$544
Esomeprazole Magnesium14$403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$386$42,47760 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$99$39,49713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 323 gastroenterology providers in Indiana.

Other gastroenterology in Bloomington

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →